Summary
Synthetic anti‐idiotypic antibodies represent a potentially valuable tool for the isolation and characterization of B cells that produce xenoantibodies. An anti‐idiotypic antibody that binds to a subset of B cells producing antibodies encoded by the variable‐region heavy chain 3 (VH3) germline genes DP35 [immunoglobulin variable‐region heavy chain 3‐11 (IGHV3‐11)], DP‐53 and DP‐54 plus a small number of VH4 gene‐encoded antibodies in humans has recently been identified. These germline progenitors also encode xenoantibodies in humans. We tested whether the small, clearly defined group of B cells identified with this anti‐idiotypic antibody produce xenoantibodies in non‐human primates mounting active immune responses to porcine xenografts. Peripheral blood B cells were sorted by flow cytometry on the basis of phenotype, and cDNA libraries were prepared from each of these sorted groups of cells. Immunoglobulin VH gene libraries were prepared from the sorted cells, and the VH genes expressed in each of the sorted groups were identified by nucleic acid sequencing. Our results indicate that xenoantibody‐producing peripheral blood B cells, defined on the basis of binding to fluorescein isothiocyanate (FITC)‐conjugated galactose α(1,3) galactose–bovine serum albumin (Gal‐BSA) and the anti‐idiotypic antibody 2G10, used the IGHV3‐11 germline gene to encode xenoantibodies and were phenotypically CD11b+ (Mac‐1+) and CD5–. This novel reagent may be used in numerous applications including definition of xenoantibody‐producing B‐cell subsets in humans and non‐human primates and immunosuppression by depletion of B cells producing anti‐Gal xenoantibodies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.